05.29.26 -- Accelerate Biologics Development With End‑To‑End Expertise

Accelerate biological breakthroughs with integrated services spanning process development, large-scale drug substance manufacturing, and high-speed aseptic fill/finish.

We are an established leader in advancing vaccines from preclinical development to commercial supply across multiple modalities and complex therapeutic platforms.

By partnering with us, you gain access to our unique, interconnected network, purpose-built to overcome the breakpoints common in traditional manufacturing models.

View how to implement USP <665> extractables testing, align with global E&L standards, and apply risk-based strategies to ensure regulatory compliance and patient safety.

Advancing biologics requires confidence in safety, quality, and compliance. Learn how integrated analytical and biosafety testing, backed by decades of expertise, helps reduce risk.

See how coordinated development — from DNA construct through IND submission —helps teams streamline decision‑making, strengthen data continuity, and prepare more confidently. 

A CDMO leader highlights two decades of growth, showcasing analytical strength, manufacturing, regulatory support, and integrated services that speed drug development.

Viral‑clearance studies need phase‑appropriate design, strong virus stocks, modality‑specific risk assessment, and alignment with evolving regulations for reliable safety outcomes.

Chemomics transforms full DEL datasets into predictive insights. Assimilate how combining large-scale screening with clear computational models accelerates SAR understanding.

Highly potent APIs require stringent containment and precise manufacturing controls. Specialized facilities offer end-to-end development solutions and robust cross-contamination protections.

An aseptic environment for diverse injectables, advanced automation, and Annex 1–aligned processes, supporting smooth transitions from development to commercial supply.